Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERIGE phase II study of eribulin + gemcitabine in first-line metastatic triple-negative breast cancer
2012-003505-10Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin, gemcitabine in triple-negative breast cancer (TNBC), breast cancer, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Oct 2012; status: completed.
02
Drugs
eribulingemcitabine
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2012-003505-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003505-10.